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Abstract
NKT cells play an important role in autoimmune diseases, tumor surveillance, and infectious diseases, providing in most
cases protection against infection. NKT cells are reactive to CD1d presented glycolipid antigens. They can modulate immune
responses by promoting the secretion of type 1, type 2, or immune regulatory cytokines. Pathogen-derived signals to
dendritic cells mediated via Toll like Receptors (TLR) can be modulated by activated invariant Natural Killer T (iNKT) cells. The
terminal b-(1–4)-galactose residues of glycans can modulate host responsiveness in a T helper type-1 direction via IFN-c and
TLRs. We have attempted to develop a defined immunotherapeutic, based on the cooperative action of a TLR ligand and
iNKT cell using a mouse model of visceral leishmaniasis. We evaluated the anti-Leishmania immune responses and the
protective efficacy of the b-(1–4)-galactose terminal NKT cell ligand glycosphingophospholipid (GSPL) antigen of L. donovani
parasites. Our results suggest that TLR4 can function as an upstream sensor for GSPL and provoke intracellular inflammatory
signaling necessary for parasite killing. Treatment with GSPL was able to induce a strong effective T cell response that
contributed to effective control of acute parasite burden and led to undetectable parasite persistence in the infected
animals. These studies for the first time demonstrate the interactions between a TLR ligand and iNKT cell activation in
visceral leishmaniasis immunotherapeutic.
Citation: Karmakar S, Bhaumik SK, Paul J, De T (2012) TLR4 and NKT Cell Synergy in Immunotherapy against Visceral Leishmaniasis. PLoS Pathog 8(4): e1002646.
doi:10.1371/journal.ppat.1002646
Editor: Eleanor M. Riley, London School of Hygiene and Tropical Medicine, United Kingdom
Received June 8, 2011; Accepted March 1, 2012; Published April 12, 2012
Copyright:  2012 Karmakar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partly supported by The Department of Science and Technology, Government of India (Grant number, SR/SO/HS-46/2004 and SR/SO/HS-
52/2007) http://www.serc-dst.org/ The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: triptide@iicb.res.in
¤ Current address: Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America
. These authors contributed equally to this work.
Introduction
Visceral leishmaniasis (VL) is a deadly disease caused by the
parasitic protozoan Leishmania donovani (LD) in India, Bangladesh,
China, Nepal and Sudan; by L. Infantum in N. Africa and Southern
Europe, and by L. chagasi in Latin America. There is a regional
variation in response to antileishmanial drugs and thus treatment
regimens vary in different regions. Except for in Europe and
antimony-unresponsive regions of India, pentavalent antimonials
are still the drug of choice. In Europe liposomal amphotericin is
used. Miltefosine is the first effective oral drug for VL. http://
www.nature.com/nrmicro/journal/v5/n11/full/nrmicro1748.
html - B119#B119Most available drugs are costly, cause severe
side toxicity, require long treatment regimens and are becoming
more and more ineffective, necessitating the discovery of new
drugs. The problem is further magnified by the emergence of drug
resistance and HIV co-infection [1,2]. One approach that has
shown promise is immunotherapy.
The disease is characterized by depressed cell-mediated
immunity (CMI) and agents which directly stimulate the
macrophage (Mw) to kill intracellular amastigotes and/or induce
the basic T-helper type 1 (Th1)-cell anti-leishmania immune
response would provide a rationale for treatment in visceral
infection [3]. Conventional CD4+ and CD8+ T cells of the
immune system recognize specific peptide antigens (Ag) bound to
major histocompatibility complex (MHC) class II or MHC class I
molecules, respectively. In contrast Natural Killer T (NKT) cells
are a unique subset of T cells that recognize glycolipid antigens
presented by CD1d molecules. NKT cells have the potential to
produce key type 1 and type 2 cytokines and are involved in the
control of several types of immune response [4–6]. It has been
suggested that IFN-c production in response to glycolipid Ag
stimulation is initiated after Toll-like-receptor (TLR) signaling of
Ag-presenting-cells (APCs) and subsequent recruitment of NKT
cells as well as other cell types [7]. The b(1–4) galactose terminal
Lewis X type glycans have the ability to modulate host responses
in a Th1 direction via NF-kBp65, IFN-c and macrophage TLRs
[8]. Binding of LD immunostimulating glycosphingophospholipid
(GSPL) Ag to the Ricinus communis agglutinin-1 (RCA-1) [9]
suggests that this glycolipid possesses terminal b1,4 linked
galactosyl residues [10]. In vitro pulsing of LD infected APCs with
GSPL, caused the activation of the Va14+CD1d1-specific NKT
cell hybridoma DN32.D3 [11]. GSPL also induced ROS and RNI
in addition to IFN-c and IL-12 in PBMC from normal individuals
[12]. Control of LD infection depends on early induction of an IL-
12-driven expansion of Th1 cells, production of IFN-c [13,14],
Mw activation and subsequent generation of reactive nitrogen and
oxygen species [15]. Because GSPL can induce type 1 cytokines
and nitric oxide (NO) generation in Mws, we tested its therapeutic
efficacy in the mouse model of VL. Our data demonstrated that
PLoS Pathogens | www.plospathogens.org 1 April 2012 | Volume 8 | Issue 4 | e1002646GSPL could confer complete protection to LD infection by an
early triggering of IL-17 and IFN-c responses of murine NKT cells
by TLR4 activated CD11c+ APCs.
Results
Importance of terminal b-(1–4)- galactose residues for
GSPL mediated protection
To explore whether terminal b-(1–4)-galactose residues were
needed for GSPL mediated protection, GSPL was treated with a
or b galactosidase. The purity of these preparations was analyzed
by 1) TLC mobility shift and 2) by lectin blotting with Erythrina
cristagalli lectin (ECL), which detects terminal b1,4-galactose
residues (Figure S1 A,B). Bone marrow-derived-macrophages
(BMDC) adhered on cover slips were infected with LD.
Therapeutic efficacy of galactosidase treated GSPL (100 mg/
mL) was compared to untreated GSPL (100 mg/mL). Intracellu-
lar parasite number in control LD infected BMDC was
43106165.44 parasites/1000 BMDC. a-galactosidase treated
(100 mg/mL) and untreated GSPL (100 mg/mL) reduced the
intracellular parasite number of LD infected BMDCs by 97.2%
and 97.5% respectively (123.66614.29 parasite/1000 BMDC
and 110.33621.59 parasite/1000 BMDC respectively). However,
commercially available position specific b-(1–4)-galactosidase
treated GSPL reduced the intracellular parasite number by only
2.7% (4237679.37 parasite/1000 BMDC). These observations
indicate that terminal b-(1–4) galactose residues play an
important role in the therapeutic efficacy of GSPL against
experimental VL. No obvious cytotoxicity was noted against
BMDC at concentrations ranging from 50–400 mg GSPL/mL/
10
6 cells (Figure S1 C). A critical function of macrophages is their
ability to phagocytose. The phagocytic ability of the BMDCs
treated with GSPL remained unaltered (Figure S1 E).
Therapeutic immunization with GSPL
GSPL binds to CD1d, restores the defective APC function in
LD-infected cells, and stimulates robust IL-2 production in
Va14Ja18 NKT hybridoma cells [16]. The evident immunomod-
ulatory property of GSPL paved the way for assessing its
antileishmanial potency in the murine model of VL. Treatment
of LD-infected BALB/c mice was initiated 8 wk post-infection
(p.i.), time when the infection was already established. LD infected
animals were divided into five groups of 20 animals each. Group I
mice received 100 mL of vehicle only. Mice in groups II received
b1,4-galactosidase treated GSPL twice at 15 days interval
(100 mg/100 mL vehicle, subcutaneous [s.c.]), Group III mice
received 100 mLo fagalactosidase treated GSPL twice at 15 days
interval (100 mg/100 mL vehicle, s.c.), Group IV received GSPL
only while group V received 100 ng/mL polymyxin/dose along
with GSPL. Fifteen days post treatment, parasite burden in the
liver, spleen, and bone marrow of each BALB/c mice was
determined. The effect of GSPL was dose dependent, being
effective at 10, 25, 50 mg/dose, and optimal at 100 mg/dose
(Figure 1 A). At 100 mg/dose, there was complete absence of
amastigotes in the impressions of stamp smears of transverse
sections of spleens and livers of 90%, and 100% animals
respectively. There was also complete absence of amastigotes in
the bone marrow smears of 90% animals (Figure 1 B). Rest of the
animals showed ,99% reduction in splenic and bone marrow
parasite burden. The reduction in parasite number was sustained
up-to 12 months post treatment, until the end of the experiment.
Up-to 12 months later, we still could not detect any liver parasite
burden, while spleen and bone marrow parasite burden was still
almost absent (Figure S2). At the end of treatment, the average
body weight in animals treated with GSPL was equivalent to
values for the control vehicle treated group (control group of mice:
25.961.1 g; treated group of mice: 26.161.2 g). There was no
appreciable change in the protective efficacy of GSPL in presence
of polymyxin B (100 ng/mL, Figure 1 A). This result rules out the
possibility that there was any LPS (lipopolysaccharide) contami-
nation in GSPL. The LAL endpoint assay further confirmed that
the GSPL preparations did not contain endotoxin (data not
shown). To further ascertain whether GSPL had conferred long-
lasting immunity, cured mice were later re-infected via the
intracardiac (i.c.) route, 8 wk after the last GSPL dose. Parasite
burden in the re-infected animals progressed rapidly in vehicle-
treated BALB/c mice, whereas GSPL-treated mice remained
resistant, as observed up to 60 days (Figure 1 C). Thus, GSPL
therapy might exert an acquired protective immunity against VL.
In order to confirm the association of terminal galactosylation
with the protective efficacy of GSPL, LD-infected BALB/c mice
(n=20) were treated with b1–4 galactosidase treated GSPL
(100 mg/dose) or a-galactosidase treated GSPL (100 mg/dose)
8 wk p.i. As shown in Figure 1 A and 1 B, treatment of GSPL with
b1–4 galactosidase resulted in only ,4.76%, 4.8% and 3.7%
reduction of hepatic, splenic and bone marrow parasite burden
respectively, while a-galactosidase treated GSPL was as effective as
untreated GSPL.
GSPL mediated protection depends on TLR4
It has been reported that the terminal b-(1–4)-galactose linked
glycans can modulate host responses in a T-helper type 1 direction
via NF-kB p65, IFNc and macrophage TLRs [8]. As GSPL
expresses b1,4-terminal galactose residues, we designed experi-
ments to determine whether TLR expression on APCs was
important for intracellular parasite killing by GSPL. Treatment of
infected BMDCs with 100 mg/mL GSPL but not b-galactosidase
treated GSPL resulted in a significant reduction in intracellular
amastigotes (96% reduction) and this reduction was notably
negated by prior treatment with TLR4/MD2 Ab (10 mg/mL), but
not TLR2 Ab (10 mg/mL) (2% and 92% reduction in intracellular
parasites respectively) (Figure S3 A). The viability (Figure S3 B)
Author Summary
Kala azar (visceral leishmaniasis) is a deadly disease caused
by the parasitic protozoa Leishmania donovani. In absence
of a suitable vaccine, the incidence of leishmaniasis has
increased. The World Health Organization observes that, if
the disease is not treated, the fatality rate in developing
countries can be as high as 100% within 2 years. Therapy
of visceral leishmaniasis can be complicated by toxic side
effects, drug resistance, and the need for prolonged
treatment regimens. Therefore, improved therapy for
leishmaniasis remains desirable. Immunotherapy to selec-
tively induce type 1 immune responses considered
essential for resistance to leishmaniasis has shown great
promise. CD1d-binding glycolipids stimulate TCR signaling
and activation of invariant natural killer T (iNKT) cells.
Terminal b-(1–4)-galactose residues in glycoconjugates
have been identified as the TLR ligand that induces IFN-c
via TLR signaling. We have used the b-(1–4)-galactose
terminal glycosphingophospholipid (GSPL) antigen from L.
donovani parasites to treat infected BALB/c mice. We
report that immunotherapy with GSPL induced IFN-c,a
type 1 cytokine, through the cooperative action of TLR4
and NKT-cells that contributed to effective control of acute
parasite burden in the infected animals.
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GSPL remained unaltered. To further assess the possible role of
TLR2 and 4 in GSPL-mediated anti-leishmanial effector response,
siRNA mediated knock-down system was used. TLR silencing was
confirmed by western blot assays (Figure 2 A). As shown in
Figure 2B, transfection of splenic adherent cells with siRNA
directed towards TLR4 but not TLR2 significantly abrogated
GSPL-mediated- parasite suppressive effect. The addition of
polymyxin B (100 ng/mL) did not alter the GSPL mediated
killing of the parasite (Figure 2 B).
Since GSPL did not confer protection in presence of TLR4 Ab
or siRNA, we evaluated therapeutic efficacy of GSPL in LD
infected TLR4 defective C3H/HeJ mice. Sixty days post-infection,
LD infected C3H/HeJ mice were treated twice at 15 days interval
with GSPL (100 mg/dose). GSPL elicited very little protection in
the C3H/HeJ mice compared with the vehicle treated mice and
the parasite load remained high in the treated mice (Figure 2 C,D).
Our findings demonstrate that TLR4 is essential for protective
immunity elicited by GSPL.
To ascertain if host responses mediated through TLR4
contribute to parasite clearance in an iNKT independent manner,
we used LPS to examine the effect of TLR4 activation on
intracellular parasite replication. Sixty days post-infection, LD
infected BALB/c mice were treated with LPS thrice (5 mg/dose or
10 mg/dose; intraperitoneal injection) on alternate days and
animals were sacrificed on days 1, 3 and 12 after the last
treatment. LPS treatment did not lead to reduced parasite burden
(Figure 2 E,F).
TLR/MyD88-dependent signaling has been implicated as
essential for the immune responses against Leishmania parasites
[17]. To determine the effect of MyD88 on TLR4 mediated
protection, BMDCs were either mock transfected or transfected
with MyD88 siRNA, infected with LD parasites followed by GSPL
treatment. GSPL-induced inhibition of amastigote multiplication
was also found to be markedly attenuated by MyD88 gene
silencing (Figure 2 B). MyD88 silencing was confirmed by western
blot assays (Figure 2 A).
GSPL induces TLR4 expression on splenic adherent cells
To determine if GSPL could modulate TLR expression, we
analysed the expression of TLR2, and 4 in LD infected GSPL
treated APCs by real-time-PCR. Stimulation with the TLR ligands
Zymosan (TLR2) and LPS (TLR4) induced increased expression
of the corresponding TLRs. GSPL treatment significantly
Figure 1. Complete cure induced in LD infected BALB/c mice following GSPL therapy. Various subcutaneous doses of GSPL were given (15
days apart) twice staring on the 60
th day after infection. Animals were sacrificed 15 days after therapy. Parasite loads of (A) liver, spleen, and (B) bone
marrow of individual animals were determined as described in the Materials and Methods. (C) The course of visceral re-infection was studied by i.c.
administration of 1610
7 LD promastigotes into naive, age-matched BALB/c mice and cured (100 mg/dose-GSPL treated) mice 8 wks post therapy.
Naı ¨ve age-matched mice infected at the time of re-infection was kept as control-1. Mice that were infected at the initiation of the experiment and did
not receive immunotherapy were kept as control-2. The progression of infection was monitored by determining the spleen and liver parasite burden
by serial dilution assay, up to 60 days after re-infection. Arrow indicates the point of re-infection (day 0). Controls were infected but not vaccinated.
Data represent the means 6 SD of 20 animals per group, and are representative of three independent experiments. p,0.0001 compared with
respective infected control groups at all time points; paired two-tailed Student’s t-test.
doi:10.1371/journal.ppat.1002646.g001
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PLoS Pathogens | www.plospathogens.org 3 April 2012 | Volume 8 | Issue 4 | e1002646Figure 2. TLR4 and MyD88 are required for GSPL induced anti-leishmanial response. (A) Splenic adherent cells were transfected with
siRNAs specific to TLR2, 4 or MyD88 (specific). A control group was transfected with control siRNA (control). Twenty-four hours after transfection,
cells were recovered and their TLR2, 4 and MyD88 levels assessed in Western blots. GAPDH in total proteins was used as loading controls. Blots are
representative of three separate experiments. (B) Splenic adherent cells transfected with TLR2, TLR4, MyD88 or control siRNA (con), were infected
with LD (APC/parasite 1:20) for 12 h. Non-ingested promastigotes were removed by washing, and adherent cells were cultured for another 36 h.
Infected APCs were then treated with GSPL (100 mg/mL) for 24 h. Intracellular parasite number was determined by Giemsa staining. Each
experiment was conducted in triplicate and repeated at least three times each and one set of representative data is shown. Error bars represent
mean 6 SD. * p,0.0001; paired two-tailed Student’s t-test. (C,D) Antileishmanial effect of GSPL on parasite growth in TLR4 deficient C3H/HeJ mice.
Sixty days LD infected C3H/HeJ mice were given two subcutaneous injections of GSPL (100 mg each) at 15 days apart. The parasite burdens in liver
(C), spleen (C), and bone marrow (D) of individual animals were then determined at 15 days after the last treatment. The results are representative
of three independent experiments and data shown are means 6 SD; n=5. *p,0.0001 versus corresponding infected control; paired two-tailed
Student’s t-test. (E,F) In vivo parasite load in liver, spleen and bone marrow of LD infected BALB/c mice treated with LPS. Sixty days LD infected
BALB/c mice were given three intraperitoneal injections of LPS on alternate days (5 mg/injection or 10 mg/injection). The parasite burdens in liver
(E), spleen (E), and bone marrow (F) of individual animals were then determined at days 1,3 and 12 after the last treatment. The results are
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infected and uninfected APCs (Figure 3 A).
We next assessed the expression of TLR proteins by flow-
cytometry. Significant numbers of CD11c
+ spleen cells expressed
TLR2 and 4. Compared to LD infected cells, there was a 2.45-fold
increase in the number of CD11c
+TLR4
+ cells on GSPL
treatment in LD infected APCs. There was also a 1.63-fold
increase in the number of CD11c
+TLR4+ cells on GSPL
treatment in the uninfected APCs, where as there was no
significant change in the expression of CD11c
+TLR2
+ cells
(Figure 3 B,C).
Induction of IL-12 on GSPL treatment
Stimulation of TLR4 induces DC maturation and strong Th1-
type responses through release of IL-12 [18]. iNKT cells isolated
from experimental animals were adjusted to 1610
5 cells/mL and
mixed with 1:10 of autologous splenic adherent cells (1610
6
adherent cells). To determine the pattern of adherent cell
composition, we performed flow cytometric analysis (Figure S4).
Adherent cells were composed of 72% Cd11b
+ cells, 7% Cd11c
+
cells and 18% Cd11b
+Cd11c
+ cell populations. The purity of the
sorted NKT cells averaged greater than 99 percent (Figure S5
Aiii). To determine whether IL-12 secretion following iNKT cell
activation correlates to in vivo induction of Th1 and Th2 cells, APC
were cultured with purified iNKT cells as described by Maruo et.
al. [19]. Culture supernatants were collected after 24 h and IL-
12p70 and IL-12p40 was measured by ELISA. There was ,10.9
and 10 fold increase in the production of IL-12p70 and IL-12p40
respectively in the GSPL treated LD infected BALB/c mice
compared to the infected control animals (Figure 4 A). IL-12p70
and IL-12p40 secretion in the GSPL treated C3H/HeJ mice were
appreciably lower compared to the cytokine levels in wild type
(WT) BALB/c mice. There was no appreciable change in IL-
12p70 or IL-12p40 expression in presence of polymyxin B
(100 ng/mL). This result rules out the possibility that there was
any LPS contamination in GSPL.
Release of IL-12 by dendritic cells (DC) activated by TLR
ligation is dependent on MyD88 signaling [20]. GSPL-induced IL-
12 production was found to be markedly attenuated by MyD88
gene silencing (Figure 4 A). There was 11 and 10 fold increase in
the production of IL-12p70 and IL-12p40 respectively by APCs
that were transfected with non-silencing siRNA control (Figure 4
A).
Since there was an increase in IL-12p40, we assessed the
expression of the IL-12 and IL-23 specific chains IL-12p35 and IL-
23p19 by real-time PCR. There was significant increase in the
expression of both IL-12p35 and IL-23p19 in GSPL treated
BALB/c mice (Figure 4 B).
Induction of host protective Th1 immune response on
GSPL treatment
For IFN-c, IL-18, TNF-a and NO estimation, iNKT cells
isolated from experimental BALB/c mice were mixed with
autologous splenic adherent cells as described above. Supernatants
from GSPL stimulated and un-stimulated cultures were collected
after 48 h for IL-18 and 72 h for IFN-c, TNF-a and nitric oxide
(NO), and the levels of cytokines were measured by ELISA and
NO by the Griess Reagent. Cells were also analyzed by
intracellular cytokine staining and NO staining with 4,5-diamino-
fluorescein diacetate. No cytokines were detected without
antigenic stimulation of spleen cell cultures. Cytokine profile at
the protein level was assessed by ELISA. Compared to the LD
infected animals, there was a 10, 4.5, 10.3 and 11.4 fold up-
regulation of IFN-c, IL-18, TNF-a, and NO respectively in the
cured BALB/c mice, where as the cytokine levels were appreciably
lower in the GSPL treated C3H/HeJ mice (Figure 5, C–F).
Intracellular cytokine levels as measured by flow cytometry
revealed a similar increase of IFN-c, IL-18, and TNF-a in spleen
cells of GSPL-treated infected animals (Figure S5). To specifically
identify iNKT cells, we gated on cells that doubly stained with
fluorescent PE–CD1d–a-GalCer tetramers and PE-Cy5-anti-
TCRb (Figure S5, C, gate R5) and analyzed intracellular FITC-
labeled cytokines in the gated populations. Consistent with our
ELISA studies, and intracellular cytokine profiles, transcript levels
for IFN-c, IL-18, TNF-a, and iNOS in spleen cells of GSPL-
treated infected animals showed similar results as assessed by real-
time PCR (Figure S6, A-D). IFN-c and NO are important
mediators of antileishmanial immunity. IL-18 has been demon-
representative of three independent experiments and data shown are means 6 SD; n=3. *p,0.0001 versus corresponding infected control; paired
two-tailed Student’s t-test.
doi:10.1371/journal.ppat.1002646.g002
Figure 3. GSPL upregulates TLR4 expression in splenic
adherent cells. Splenic adherent cells were infected with LD
promastigotes (24 h) at 20:1 parasite-to-splenic cell ratio followed by
treatment with 100 mg/mL of GSPL, b-galactosidase treated GSPL
(Gal
2GSPL) or GSPL along with 100 ng/mL Polymixin B (GSPL+PB) for
9 h. TLR expressions were also evaluated in unstimulated splenic
adherent cells and adherent cells stimulated with GSPL, Zymosan (TLR2)
or LPS (TLR4) for 9 h. TLR expression was evaluated by real-time PCR (A)
and flow cytometry (B) for individual cover slips. Bar graphs in B show
the percent of CD11c+ cells expressing TLR2 or TLR4 in splenic adherent
cells. The results are representative of three independent experiments.
Error bars represent mean 6 SD, n=3. * p,0.0001; paired two-tailed
Student’s t-test.
doi:10.1371/journal.ppat.1002646.g003
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IFN-c production mediated by either NKT or NK cells [21–23].
To investigate if IL-12, IL-18, or Il-23 enhanced IFNc production,
we examined the effect of neutralizing anti IL-12, anti IL-18 or
anti IL-23 Abs on IFNc production. Significantly lower levels of
IFN-c were produced when cultures of BALB/c cells were
incubated with either anti IL-12p70, anti IL-18 or anti IL-23p19
antibody (10 mg/mL) (Figure 5 C, Figure S5). Treatment with
Figure 4. Induction of iNKT cell mediated IL-12 production by splenic adherent cells. Sixty days LD infected animals were treated with
GSPL as described in the legend of Figure 1. (A) Animals were sacrificed 15 days after the last treatment and iNKT cells isolated from individual
experimental animals (WT BALB/c and C3H/HeJ mice) were mixed with 1:10 of autologous splenic adherent cells (1610
6 adherent cells) and were
cultured in 24-well culture plates containing 100 mg/mL GSPL for 24 h. Culture supernatants were assayed for the concentration of IL-12p70 and IL-
12p40 in ELISA. The results are representative of three independent experiments and data shown are means 6 SD; *p,0.0001 versus corresponding
infected control; Student’s t-test. (B) mRNA expression of IL-12p40, IL-12p35, and IL-23p19 in the spleen of each GSPL treated LD infected animals was
evaluated individually by real-time PCR. The fold up-regulation of mRNA post-GSPL treatment was calculated by normalizing the amount of cytokine
mRNA with the housekeeping gene GAPDH, and comparing results from treated to infected; *p,0.0001; paired two-tailed Student’s t-test. (means 6
SD (n=3) of one from three independent experiments are shown).
doi:10.1371/journal.ppat.1002646.g004
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shown).
To define the physiologic role of IL-12, IL-18 and IL-23 in
GSPL mediated protection, we further examined the effect of
neutralizing anti-IL-12, anti IL-18 and anti IL-23 Abs on LD
infected mice. Administration of the Abs significantly abrogated
the protective efficacy of GSPL (Figure S7).
Since, the C17.8 antibody has the potential to recognize the p40
subunit of both IL-12 and IL-23 (composed of p19 and p40) we
knocked down IL-12p35, and IL-23p19 in BMDC with IL-12p35
and IL-23p19 specific siRNAs respectively, infected the BMDCs in
vitro for 48 h before treating with 100 mg/mL GSPL. Cytokine
silencing was confirmed by real-time-PCR (Figure 5 A). The data
were normalized using the housekeeping gene GAPDH. IFN-c
produced by LD-infected GSPL treated control BMDC (un-
transfected) was 1039.76123.10 pg/mL. Transfection of BMDC
with IL-12p35 or IL-23p19 specific siRNAs resulted in a
significant reduction in IFNc production (Figure 5 C, insert).
Transfection with scrambled siRNA did not have any effect on
IFN-c secretion. Transfection efficacy was determined using
FITC-labeled scrambled siRNA control. The transfection efficien-
cy was quantified by flow-cytometry. As shown in Figure 5B,
FITC-labeled control siRNA successfully transfected .93% of the
cells. Since IFN-c is needed for optimal induction of NO, a
predicted consequence of IFNc down-regulation was a significant
reduction in NO production (data not shown).
Th2 and Th17 related cytokines
GSPL treatment significantly enhanced the expression of IL-
17A, TGF-b and IL-6 in the LD-infected BALB/c mice. This was
reflected in a 4.2, 4.7 and 2.4 fold increases in IL-17A, TGF-b and
IL-6 protein detected by ELISA in culture supernatants (Figure 5
G–I). Though IL-4 expression was comparable in the infected and
cured groups (Figure 5 J, IL-13 level was higher in the cured group
of BALB/c mice (Figure 5 K). The elevated IL-10 expression in
the infected BALB/c mice declined in the cured group of mice
(Figure 5 L). There was no appreciable change in cytokine
expression in the GSPL treated and untreated LD-infected C3H/
HeJ mice (Figure 5, G–L). Similar results were obtained when the
intracellular cytokine and mRNA transcripts levels of the infected
and cured groups was compared (Figure S5, S6).
IL-17
+-NKT cells in GSPL mediated cure
It has been suggested that a rapid innate IL-17 production by
NKT cells precedes the adaptive IL-17 response [24]. To explore
this probability, GSPL stimulated spleen cells from infected and
GSPL treated cured animals were fractionated into CD1d-
aGalCer tetramer
+ iNKT cells and iNKT cell depleted popula-
tions. iNKT cells were purified using MACS beads followed by
FACS sorting. To specifically identify iNKT cells, we gated on
cells that doubly stained with fluorescent PE–CD1d–a-GalCer
tetramers and PE-Cy5-anti-TCRb (Figure 6 A–C). We gated
further on the CD1d-a-GalCer
2 PE-Cy5-anti-TCRb
+ PE-CD4
+
(Figure 6 D) and analysed IL-17A production in both the gated
populations. Kinetics of IL-17A production in cultured superna-
tants of iNKT cells or iNKT
2 CD4
+ TCRb
+ cell populations
(1610
5 cells/mL) co-cultured with 1:10 of autologous splenic
adherent cells revealed that there was significant IL-17A
production by NKT cells from cured mice within 6 h that reached
a plateau by 24 h (Figure 6 E), while within iNKT
2CD4
+TCRb
+
populations in these mice, though there was very little IL-17A
production up to 24 h, IL-17 production markedly increased
thereafter (Figure 6 F). Though mouse TH17 cells have been
reported to require IL-6 and transforming growth factor-b (TGF-
b) for lineage commitment and IL-23 for maintenance, the early
production of IL-17 by NKT cells is independent of IL-6 [24].
Consistent with an expandable role for IL-6 in the expression of
IL-17 by NKT cells, IL-6 neutralization (20 ng/200 mL) did not
effect the expression of IL-17A in NKT cells (Figure 6E), though
IL-17A secretion from iNKT
2 CD4
+ cells was almost completely
inhibited when the cells were pretreated with an anti-mouse IL-6R
Ab (1 mg/mL) (Figure 6 F). Treatment with isotype control Abs
did not have any effect on IL-17A production by T cells (data not
shown). A similar IL-17A expression profile of iNKT and
Figure 5. GSPL treatment induces iNKT cell mediated Th1/Th17
cytokines in BALB/c. iNKT cells isolated from experimental animals
were mixed with autologous splenic adherent cells as described for
Figure 4. Cells were stimulated with GSPL at 100 mg/mL for the time
periods as mentioned in the text. Cytokines and NO in spleen cell
culture supernatants of five individual animals from each group were
determined by ELISA and Greiss assay method, respectively. (A) Splenic
adherent cells were transfected with siRNAs specific to IL-12p35 or IL-
23p19 (cytokine). A control group was transfected with control siRNA
(c). Twenty-four hours after transfection, cells were recovered and their
cytokine levels assessed by real-time PCR. GAPDH in total proteins was
used as loading controls. Data is the representative of three separate
experiments. (B) Transfection efficacy was quantified using FITC-labeled
scrambled siRNA control and flow-cytometry. (C) Requirement of IL-12
and related cytokines in IFN-c production by collaboration between
Va14
+ NKT cells and APCs. Anti IL-12p70, anti IL-18 and anti IL-23p19
Abs or isotype controls (data not shown) were added to parallel
cultures and IFN-c production was assessed in the supernatant by
ELISA. Adherent cells were transfected with IL-23p19, IL-12p35 and
control siRNA and IFN-c production was assessed (C, insert). D, IL-18; E,
TNF-a; F, NO; G, IL-17A; H, TGF-b; I, IL-6; J, IL-4; K, IL-13 and L, IL-10
expressions. Data represent the mean 6 SD for five animals per group.
(*p,0.0001 versus corresponding infected control; paired two-tailed
Student’s t-test). Data are representative of three experiments.
doi:10.1371/journal.ppat.1002646.g005
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2CD4
+ TCRb
+ cells was also reflected in terms of protein
secretion as determined by ELISA (Figure S 8).
TLR4/IL-23p19 mediated IL-17 induction
Based on the knowledge regarding the role of TLR4 in IL-
23p19 mediated IL-17 expression by iNKT cells [25], we wanted
to assess whether TLR4 signaling was critical for IL-23p19
mediated IL-17A production in GSPL treated LD-infected BALB/
c mice. iNKT cells (1610
5 cells/ml, isolated from experimental
animals) co-cultured with 1:10 of autologous splenic adherent cells
were stimulated with GSPL (100 mg/mL). There was an up-
regulation of IL-17A protein expression from 603.67622.94 pg/
mL in infected group of animals to 5209.336316.09 pg/mL in the
cured group. Ab neutralizing anti-IL-23p19 (10 mg/mL) abrogat-
ed IL-17A expression in GSPL-pulsed iNKT cell-autologous
adherent cell co-culture from cured group of animals (Figure S9).
Silencing of IL-23p19 expression in adherent cells by IL-23p19
specific siRNA transfection before setting up adherent cell-
autologous non-adherent cell (iNKT cells) co-culture also abated
IL-17A secretion (Figure S9). Isotype control or scrambled siRNA
transfection did not have any effect on IL-17A expression.
These results suggested that IL-17A may play a role in GSPL
therapy against experimental VL. We therefore examined the
effects of IL-17A depletion on the development of GSPL mediated
cure in mice given an experimental LD infection. LD infected
animals were treated with neutralizing antibodies against IL-17A.
IL-17A depleted animals had significantly higher organ parasite
burden compared to mice treated with the isotype control
antibody (p,0.0001) at day 15 post-treatment (Figure 7 A,C).
These results suggest that IL-17 may be important for optimal
protective immune responsiveness during GSPL therapy.
Role of IFN-c during GSPL mediated cure
From the results it appeared that GSPL conditioned spleen cells
drive concurrent IFN-c and IL-17A. To assess the direct role of
IFN-c in GSPL mediated protection, LD infected BALB/c splenic
macrophages adhered on cover-slips (45786115.53 parasites/
1000 adherent cells) were treated with GSPL in presence and
absence of anti IFN-c Ab. While single exposure to 100 mg/mL
GSPL for 24 h post-infection, reduced the intracellular parasite
load to virtually zero (4.5261.0 parasites/1000 adherent cells), 1 h
pre-treatment with 20 ng anti IFN-c significantly abrogated the
GSPL mediated protection (4342.66173.44 parasites/1000 ad-
herent cells). Further evidence for the critical role for IFN-c in the
control of LD infection comes from the demonstration that GSPL
treatment failed to cure infection in IFN-c knockout (KO) mice
(Figure 7 B,D). Treatment of LD infected C57BL/6 WT mice with
GSPL (100 mg/dose) resulted in complete absence of promasti-
gotes in the serially diluted spleen cell cultures till 21 days of
observation (Figure 7 B) in 4 out of 5 animals, while there was no
parasite detected in the liver of the animals treated with GSPL.
Thus, IFN-c deficiency completely abrogated the GSPL mediated
protection.
Role of CD40-CD40L interaction in GSPL immunotherapy
IL-12 production as a result of DC-iNKT cell interaction
requires ligation of CD40 by CD40L. To determine the
involvement of CD40-CD40L (CD154) ligation, we analyzed the
Figure 6. Kinetics of IL-17A production by iNKT cells of cured mice. Sixty days LD infected animals were treated with GSPL as described in
the legend of Figure 1. Animals were sacrificed 15 days after the last treatment. NKT cells from spleens of individual experimental BALB/c (A) mice
were identified as a-GC/CD1d tetramer
+TCRb
+ cells and after enrichment by magnetic cell sorting (B) were further purified by FACS sorting (C). The
NKT
2 populations were identified as TCRb
+CD4
+ cells (D). Isolated (E) iNKT cells or (F) iNKT depleted cell populations (R5, TCR-b
+CD4
+) were co-
cultured with 1:10 of autologous splenic adherent cells as described for Figure 4. Cells were stimulated with GSPL at 100 mg/mL, 6 IL-6 Ab (E) or 6 IL-
6R Ab (F) for the time periods indicated and intracellular IL-17A was assessed using FACS analysis. Numbers above the horizontal bar indicates the
mean fluorescence intensity and number below the bar indicates the percentage of IL-17 positive cells in the gated populations. Results show mean
6 SD of three individual mice per group; paired two-tailed Student’s t-test. Results of one from three independent experiments are shown.
doi:10.1371/journal.ppat.1002646.g006
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mice were treated with anti IL-17A Ab or isotype control Ab on days 21, 0, and +1 of GSPL treatment. The parasite burdens in (A) liver, spleen, and (C)
bone marrow was then determined at 15 days after the last treatment. (B) Sixty days LD-infected WT C57BL/6 (WT) and IFN-c KO mice were treated
with GSPL and the parasite burdens in liver, spleen, and (D) bone marrow was then determined at 15 days after the last treatment. Experiments were
repeated three times with three mice per group. The data are presented from individual mice of all three groups. *p,0.0001 versus corresponding
infected control; paired two-tailed Student’s t-test. T, GSPL treated; I, LD infected.
doi:10.1371/journal.ppat.1002646.g007
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respectively from GSPL treated and untreated LD infected BALB/
c mice. On GSPL treatment, CD40 and CD154 expression
increased on the surface of DC (36.19%) and T (27.63%) cells
respectively, as compared to the LD infected animals (2.1% and
5.4% respectively) (Figure 8A). As shown earlier, GSPL treatment
resulted in an increase in IL-12 production. Blocking CD40-
CD40L interactions with anti CD40L mAb inhibited IL-12
Figure 8. CD40-CD40L ligation augments IL-12 production in GSPL immunotherapy. (A) Comparison of CD40 and CD40L expression in
CD11c+ APC and CD3+ T cells respectively between infected and cured animals. Sixty days LD infected animals were treated with GSPL as described
in the legend of Figure 1. Animals were sacrificed 15 days after the last treatment and expression of CD40 and CD40L was studied in CD11c+ APC and
CD3+ T cells respectively (B) Splenocytes from infected and cured animals were stimulated with GSPL. Anti CD40L or isotype controls were added to
parallel cultures and IL-12p40 was assessed in the culture supernatants by ELISA. IL-12p40 was also measured in the culture supernatants of splenic
adherent cells (AC) in absence of T-cells. The results are representative of three individual mice per group and data shown are means 6 SD;
*p,0.0001 versus corresponding infected control; paired two-tailed Student’s t-test. Results of one from three independent experiments are shown.
doi:10.1371/journal.ppat.1002646.g008
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matched control antibody showed no effect on IL-12 production.
Adherent cells lacking T cells isolated from the cured animals did
not produce IL-12p40 (,45 pg/ml) on in vitro stimulation with
100 mg/mL GSPL. These results indicated that the CD40-CD40L
dependent IL-12 production in splenocytes occurred as a result of
a direct cognate interaction between T cells and adherent cells.
Discussion
Glycolipid activated iNKT cells are capable of producing both
Th1 and Th2 cytokine responses. The stimulatory Th1/Th2
balance is dictated by the presence of other maturation stimuli
simultaneously acting on DCs [26]. Although, interaction of the
same iNKT cells with the DCs in the presence of simultaneous
TLR4 stimulation significantly enhances proinflammatory DC
maturation and IL-12 secretion [26], the therapeutic implication
of this phenomenon has not been exploited.
Previous studies have indicated a rather controversial role of the
CD1d-restricted NKT cells in VL. Studies in CD1d-deficient
BALB/c mice suggested that NKT cells were required for efficient
control of hepatic LD infection [27], while, CD1d-restricted NKT
cells have been reported to play only a minor physiological role in
experimental VL in C57BL/6 mice [28]. Previous work from our
group has shown that stimulation of NKT cells by GSPL requires
the presence of CD1d [11]. Here we show that stimulation of
NKT cells and TLR4 by Leishmania glycolipid Ag GSPL leads to
the production of IFN-c and IL-17A and the subsequent clearance
of organ parasite burdens in a mouse model of experimental VL
(Figure 9). In the BALB/c mouse model infected i.c. with L.
donovani it has been reported that the liver parasite load reaches a
maximum around 2-month post-infection period following which
it starts declining, while parasite load in the spleen increases up to
4 months and thereafter the animals maintain chronic infection
with decreased parasite load for many months, if not for life. [29].
On the other hand, VL induced by intravenous inoculation of
parasites results in a faster clearance of liver parasite burden that
peaks at 4 wks p.i. [29]. In the early stage of infection, in absence
of activated T cells, number of parasites in the liver reaches a peak.
With the acquisition of a granulomatous response at the later stage
of infection, the liver parasite burden decreases [30]. In contrast to
the liver, 50% of the ingested parasite inoculum is killed by the
marginal zone macrophages within the first 24 h. Failure to
activate intrinsic leishminicidal mechanism together with the
Figure 9. Role of NKT-cells in GSPL mediated therapy. Recognition of GSPL via TLR4 results in IL-12 release by CD11c
+APCs. GSPL recognized
in the context of CD1d molecules stimulates iNKT-cells through their invariant T cell receptor (TCR). Upon activation, NKT cells rapidly secrete
cytokines such as IFN-c and IL-17A, and together with CD40-CD40L interaction, induce activation of CD11c
+APCs. Thus, GSPL may activate NKT-cells
via CD1d-dependent and TLR-4-dependent mechanisms and these mechanisms can co-operate to enhance the efficacy of GSPL mediated
immunotherapy by augmenting the NKT driven immune responses.
doi:10.1371/journal.ppat.1002646.g009
Immunotherapy against Visceral Leishmaniasis
PLoS Pathogens | www.plospathogens.org 11 April 2012 | Volume 8 | Issue 4 | e1002646inability to develop granulomatous immune effector responses
contribute to the failure of the spleen to resolve VL [30]. The sixty
days infected murine model of leishmaniasis was used since we
reasoned that an efficient therapeutic agent should be able to
control the splenic parasite burden.
The importance of the membrane-associated LD glycolipid Ag
GSPL comes from previous results, demonstrating that GSPL 1)
can induce Th1 cytokines and NO generation in Mw [12], and 2)
can stimulate robust IL-2 production in Va14Ja18 NKT
hybridoma cells [11]. Since lack of anti-Leishmania CMI has been
considered a hallmark of VL [31], parasite antigens that can
control Th2 expansion and promote the predominance of a Th1
type of response should be potential candidates for specific
immunotherapy. Two subcutaneous (s.c.) inoculations of GSPL
(100 mg each) 15 days apart completely cleared intracellular LD
parasites in BALB/c mice. Successful therapy should not only kill
the intracellular amastigotes, but should also prevent post-
treatment relapse. GSPL treated animals remained parasite-free
up-to 12 months post-treatment.
The ability to switch between type1 (IFN-c) and type 2 (IL-4)
cytokines emphasizes the immunological regulatory role that the
NKT cells play. The mechanism by which NKT cells select the
cytokines they secret are not well characterized. Cytokine response
induced by stimulated DCs is influenced by pattern recognition
[32]. Pathogen-associated molecular patterns (PAMP) that directly
stimulate DCs via TLRs act together with signals from activated
iNKT cells to influence the quality of immune responses induced
[33]. Terminal b-(1–4)-galactose residues in glycans have been
identified as the ligand that can induce IFN-c via TLR signaling
[8,34]. Presence of terminal b1,4 linked galactosyl residues in
GSPL has been previously reported [9]. We have reported
previously that GSPL stimulates iNKT cells [11]. Conclusive
evidence that terminal b-(1–4)-galactose residues are involved in
GSPL mediated protection was provided by the observation that
enzymatic removal of the terminal galactose completely abrogated
protective efficacy of GSPL.
TLR4 expression is low in the macrophages and DCs and has
been shown to be regulated by inflammatory cytokines [35]. As
TLRs are instrumental in both launching innate immune
responses and influencing adaptive immunity [36], regulation of
TLR expression may be important in the pathophysiology of VL.
Gene knockout studies in mice have suggested that TLR signalling
is essential for the immune responses against Leishmania parasites
[17]. A number of in vitro and in vivo studies have already
documented the importance of various TLRs in host defence
against different forms of leishmaniasis [37–43]. Further, TLRs
have the potential to act as therapeutic targets. In the recent years,
TLR agonists are being developed for the treatment of cancer,
allergies and viral infections and as adjuvants to enhance immune
responses against tumors and infectious diseases [44]. GSPL
induced the expression of TLR4 but not 2 in infected BMDCs and
silencing of TLR4 markedly attenuated the leishmanicidal activity
of GSPL, thereby suggesting the importance of downstream
TLR4-dependent signaling in anti-leishmanial effector response.
To further substantiate the role of TLR4 in protection against VL,
we compared the protective efficacy of GSPL in LD infected
TLR4 defective C3H/HeJ and WT BALB/c mice. GSPL
mediated protection was completely abrogated in C3H/HeJ
TLR4 mutant mice. To address the question whether iNKT
independent TLR4 dependent immune response is essential for
parasite clearance, LD infected BALB/c mice were treated with
LPS. However, since LPS could not substitute for GSPL, it
appears that GSPL mediated activation of TLR4 is required to
bring about the protection seen.
Resistance against Leishmania infection remains largely associat-
ed with an IL-12 induced type-1 response [45]. TLR signals APCs
to produce high levels of IL-12 [46,47]. In our study IL-12 was
completely down-regulated in the AG83- infected mice, whereas
high levels of IL-12p40 and IL-12p35 mRNA transcripts and IL-
12p70 and IL-12p40 proteins were found in GSPL treated cured
BALB/c mice. Very little IL-12 could be detected in the C3H/
HeJ mice. Release of IL-12 by DCs activated by TLR ligation is
dependent on MyD88 signaling [20]. Inhibition of MyD88,
strongly inhibited GSPL mediated parasite suppressive effect in
infected BMDCS.
Interaction of PAMPs with Mws and DCs via TLRs results in a
type 1 like response [30,48,49]. The cooperative stimulation of
TLR and iNKT cells resulted in Th1 skewing on GSPL
immunotherapy. There was an up-regulation of the type 1
cytokine IFN-c, IL-12, IL-18 and IL-23 with a concomitant
decrease in the disease promoting IL-10. Besides IL-12, cure is
associated with strong IFNc responses in the absence of IL-10
[50]. Evidence for the critical role for IFN-c in the GSPL
mediated control of LD infection came from the demonstration
that IFN-c knockout (KO) mice failed to cure infection. IFN-c
production by NKT cells is a consequence of the synergistic action
of IL-18 with IL-12, or IL-23 produced by PAMP stimulated APC
[23]. Our results indicated that APCs after binding of PAMPs
became primed to subsequently produce large amounts of IL-12,
IL-18, and IL-23 and thus amplified IFN-c production. This
conclusion is supported by the finding that IFN-c production
decreased in presence of anti IL-12, anti IL-18 and anti IL-23 Ab.
IFN-c derived from iNKT cells inhibits the growth of intracellular
microbes by stimulating infected APCs to synthesize NO [51]. IL-
12 and IL-18 augment this response. There was 11.4 and 13.5 fold
increase in the expression of NO and iNOS transcript respectively
in the cured BALB/c mice in comparison to the infected animals.
Although IL-4 and IL-13 are associated with development of
type 2 immune responses in models of cutaneous leishmaniasis
[52,53], there are many conflicting reports of both IL-4 and IL-13
having opposite roles to play in VL [54–56]. Though IL-4
production was comparable in the infected and cured mice, there
was a 2 fold increase in IL-13 production in the GSPL treated
BALB/c mice.
In addition to classical Th17 cells, NKT cells also produce IL-
17 [24,57]. Early production of IL-17A by CD1d-aGalCer-
tetramer
+TCR-b
+ iNKT cells from cured animals validated the
earlier findings that innate IL-17 production by NKT cells is rapid
and precedes the adaptive IL-17 response [24]. In addition, in vivo
GSPL treatment also produced TCR-b
+CD4
+ T cells capable of
producing IL-17A. Early production of IL-17A by iNKT cells was
independent of IL-6, while CD4+ T cells produced IL-6
dependent IL-17A. This was in agreement with the previous
finding that alpha-galactosylceramide stimulated naive IL-6(2/2)
splenocytes produces normal amounts of IL-17 during the first
24 h of culture [24]. IL-23 is known to promote the production of
IL-17 by NKT cells mainly in a TLR2/4-dependent manner [25].
IL-17A production by iNKT cells from cured animals decreased in
presence of anti IL-23p19 Ab or IL-23p19 specific siRNA.
Interaction of iNKT cells with DCs, in the presence of
simultaneous TLR4 stimulation, enhances IL-12 secretion through
CD40–CD40L interaction [26]. In the present study we observed
that IL-12 production in vivo is dependent on CD40:CD40L
ligation in GSPL-treated mice.
Together, these results indicated that TLR4-NKT cell syner-
gism mediated GSPL induced host-protective immunological
response in experimental VL. The innate immune component of
GSPL immunotherapy required dual activation of the IL-12/IFN-
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induced IL-17A, while GSPL induced IFN-c production by NKT
cells required the simultaneous TLR receptor signaling through
MyD88/CD40-CD40L, and secretion of IL-12.
Materials and Methods
Ethics statement
Use of both mice and hamsters was approved by the
Institutional Animal Ethics Committee of Indian Institute of
Chemical Biology, India (Accreditation Number 147/1999/
CPCSEA). All animal experimentations were performed
according to the National Regulatory Guidelines issued by
CPSEA (Committee for the Purpose of Supervision of
Experiments on Animals), Ministry of Environment and Forest,
Govt. of India.
Animals, parasites and animal infection
Four to 6 wk old BALB/c mice or C57Bl/6 mice (irrespective of
sex, originally bought from Jackson Laboratory, Bar Harbour,
Maine), reared in the Indian Institute of Chemical Biology facility
were used, with prior approval of the animal ethics committee of
the Institute. C57Bl/6-background IFN-c KO mice and TLR4
defective C3H/HeJ mice were a kind gift of Prof. A. Surolia
(National Institute of Immunology, New Delhi). The cells of IFN-c
KO mice reproducibly did not produce detectable IFN-c under
optimal stimulatory conditions (not shown). Pentavalent antimony-
responsive AG83 (MHOM/IN/83/AG83) was used for experi-
mental infection [11]. Parasites were maintained in golden
hamsters as previously described [11]. Promastigotes obtained
after transforming amastigotes from infected spleen, were
maintained in M199 [11]. Animals were infected via the
intracardiac (i.c.) inoculation of LD promastigotes [16]. Splenic
and hepatic parasite burden in infected animals were determined
as described [16], and results were expressed as mean parasite
number 6 standard deviation. For bone marrow, the parasite
burden was determined microscopically, as the number of
parasites per 1,000 host nuclei in smears.
Purification of GSPL
GSPL was purified from AG83 promastigote membranes as
described [11]. In short, late log phase promastigote membrane
(1 g wet weight) was extracted with 19 vol of chloroform:metha-
nol:ethyl acetate:pyridine:4.5N ammonia:water (15:15:5:0.5:0.5:
0.5, v/v; Solvent A). Anionic glycolipids were eluted from a
DEAE-Sephadex A-25 column with a gradient of KCl in 0.01 M
phosphate buffer, pH 6.4, containing 0.05 N ammonium hydrox-
ide and 0.1% sodium salt of taurodeoxycholic acid. The anionic
glycolipids were loaded onto a silicic acid column and the
glycophosphosphingolipid (GSPL) was eluted with C:M (4:6, v/v)
and further purified on a RCA-1-Sepharose 4B affinity column.
GSPL was eluted with 0.1 M Galactose in Solvent A. Purity of
GSPL was checked by HPTLC developed in three different
solvent systems, Solvent B, C and D. (Solvent B, chloroform :
methanol: 0.25N ammonia in 0.25% KCL(65:45:9); Solvent C,
pyridine:ethyl acetate:acetic acid:0.25% KCl (36:36:7:21, v/v),
Solvent D, 1-butanol:pyridine:0.25% KCl (3:2:1, v/v). Plates were
sprayed with either the diphenyl amine reagent for glycolipids [58]
or Dittmer and Lester reagent for phospholipids [59].
Endotoxin detection in the GSPL preparations
The endotoxin level of 100 mg/L GSPL preparation was less
than 0.1 endotoxin units (EU)/mL as measured by chromogenic
Limulus amoebocyte lysate (‘LAL’) endpoint assay (QCL-1000;
BioWhittaker, MD, USA) following the manufacturer’s manual.
BMDC infection
BMDC was generated from bone marrow progenitors in the
presence of rmGM-CSF and rmIL-4 [11]. A total of 10
6 non-
adherent bone marrow cells/ml, collected after passage of marrow
from the tibias and femurs of BALB/c mice, were seeded in a 24-
well plate in the presence of rmGM-CSF (150 U/ml) and rmIL-4
(75 U/ml) and then cultured for 3 days in a 37uC incubator with a
5% CO2 supply. On day 3, nonadherent cells (2.5610
6/2 ml/
well) were again transferred and supplemented with complete
medium and cytokines, and subsequently cultures were fed with
rmGM-CSF and rmIL-4 on days 5 and 7. After 10 days, the
nonadherent cells expressing CD11c assessed by flow cytometry
(data not shown) were collected. During the last 24 h of BMDC
culture, the cells were grown in the presence of rmTNF-a (20 ng/
ml), providing DC maturation stimulus.
For in vitro infection of BMDCs, cells were seeded on glass
coverslips inside 6-well culture plates to a final number of 2610
5
cells per well. Cells were infected with stationary phase 2
nd passage
LD promastigotes at a parasite/APC ratio of 20:1. The cells were
incubated at 37uC with 5% CO2. Following 12 h incubation, non-
internalized promastigotes were removed by washing with PBS
and cells were incubated for another 36 hours using the same
culture media. Forty eight hours parasitized APCs are used
throughout the study. Cell viability was assessed using an MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)-
based colorimetric assay kit (Roche Applied Science, Indianapolis,
IN, USA) according to the manufacturer’s instructions. GSPL was
dried from solution in organic solvent by rotary-evaporation under
reduced pressure and re-dissolved in PBS. After brief sonication,
the sample micellar solution was added to the culture medium at
the selected concentrations for in vitro work. Infected BMDCs were
treated with the indicated concentration of GSPL for 24 h, the
coverslips with the attached infected cells were removed, washed
with saline solution, fixed and stained with Giemsa. The average
number of intracellular parasites per 1000 BMDC was calculated
by counting the cells per coverslip.
Phagocytic activity assay
The macrophages were tested for their ability to ingest
fluorescein isothiocyanate-labelled Latex beads using the Phago-
cytosis Assay Kit (Cayman, Ann Arbor, Michigan, USA)
according to the manufacturer’s instructions. The fluorescence
was determined using a fluorescence microscope equipped with
filters for detecting excitation and emission at 483 nm and
535 nm, respectively. We ensured that the fluorescence measured
accounted exclusively for ingested particles, as the signal
potentially generated from any non-internalized bioparticles was
quenched by the addition of trypan blue, as supplied by the
manufacturer.
Treatment of BMDC with anti TLR antibody
Infected BMDCs were pretreated with anti-TLR4 monoclonal
antibody (with a final concentration of 10 mg/mL; clone MTS510,
eBioscience), or an isotype matched control (rat IgG2ak,
eBioscience), for 1 h, then washed, three times, with PBS solution.
Subsequent, identical steps were taken with the GSPL treated
groups. The anti TLR2 monoclonal antibody group was similarly
pretreated with anti TLR2 antibody (10 mg/mL, clone mT2.7,
eBioscience) or an isotype matched control (mouse IgG2ak,
eBioscience) for 1 h, prior to treatment with GSPL.
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BALB/c mice were infected with 1610
7,2
nd passage LD
promastigotes in saline through the i.c. route. LD infected animals
were divided into five groups of 20 animals each. Sixty days p.i.,
animals were injected twice at 15 days interval with 100 mg
GSPL/100 mL PBS through the s.c route. Group I mice received
100 mL of vehicle only. Mice in groups II received b1,4-
galactosidase treated GSPL twice at 15 days interval (100 mg/
100 mL vehicle, subcutaneous), Group III mice received 100 mLo f
agalactosidase treated GSPL twice at 15 days interval (100 mg/
100 mL vehicle, s.c.), Group IV received GSPL only while group V
received 100 ng/mL polymyxin/dose along with GSPL. Fifteen
days after the last injection, animals were sacrificed and hepatic
and splenic parasite burden was determined from impression
smears following methanol fixation and Giemsa staining. For the
spleen and liver, the parasite burden was expressed as Leishman-
Donovan units (LDU),of Stauber on Giemsa-stained imprints
(LDU=number of amastigotes/1000 cells nuclei x mg organ
weight), as well as by the limiting dilution method [11]. A weighed
piece of spleen or liver from experimental animal was first
homogenized between two sterile frosted glass slides in complete
M199 medium and diluted with the same medium to a final
concentration of 1 mg/mL. Ten-fold serial dilutions of the
homogenized tissue suspensions were then plated in 96-well plates
and incubated at 22uC for 2–3 wk. Wells were examined for viable
and motile promastigotes at a 3-day interval, and the reciprocal of
the highest dilution that was positive for parasites was considered
to be the parasite concentration per milligram of tissue. The total
organ parasite burden was calculated using the weight of the
respective organs.
LPS treatment
Sixty days LD infected mice were treated with 5 mg/dose or
10 mg/dose LPS (intraperitoneal, Escherichia.coli 055:B5, Sigma)
on days 0,2 and 4 and animals were sacrificed on days 1, 3 and 12
after the last treatment. Parasite loads of liver, spleen, and bone
marrow of individual animals were determined as mentioned
above.
Galactosidase treatment
Galactosidase treatment was performed using 500 mg GSPL.
Treatment with a-galactosidase (G8507, Sigma-Aldrich, St.Louis,)
was carried out using 90 mU of enzyme and p-nitrophenyl a-D-
galactopyranoside as a positive control. Treatment with positio-
naly specific b1–4 galactosidase (G-0413, Sigma-Aldrich,
St.Louis,), was carried out using 9 mU of enzyme and p-
nitrophenyl b-D-galactopyranoside as the positive control. For
all enzyme treatments both the treated sample and an identical
negative control were worked up in tandem using the manufac-
turer’s recommended conditions. The hydrolysates were centri-
fuged (20000 g, 4uC, 15 min), and the glycosphingolipids (GSL)
were precipitated in cold acetone for 24 h at 4uC. The resulting
GSL pellets were further purified by preparative TLC and purified
compounds were confirmed by TLC. 10 mgo fa/b-galactosidase-
treated and untreated samples were run on TLC. Plates were
resolved using a solvent system of chloroform:methanol:0.25N
ammonia in 0.25% KCL(65:45:9) (v/v). Typically, two chromato-
grams were developed in parallel on the same HPTLC plate. One
was sprayed with the diphenylamine-aniline-phosphoric acid
(DPA) spray reagent [60] and the other was transferred to
polyvinylidiene difluoride membrane (PVDF) by TLC blotting
[61] and overlaid with biotinylated Erythrina cristagalli lectin. The
plates were then immersed in buffer B (0.01 M Na2HPO4,
0.14 M NaCl, 2% polyvinylpyrrolidone-40 [pH 7.2]) for 1.5 h at
room temperature with gentle stirring (20 rpm). Plates were then
incubated with biotinylated E.cristagalli lectin (10 mg/ml, 24 h,
Vector Laboratory), followed by incubation with streptavidin-
HRP(2 h, GE Biosciences) and visualized using a luminol-based,
light-producing reaction generated with the enhanced chemilumi-
nescent detection reagent for horse-raddish peroxidase (Pierce). A
shift in the chromatographic mobility of b-galactosidase-treated
GSPL was observed (Figure S1 A, lane3).
Real-time RT-PCR
Total RNA was isolated from splenic lymphocytes of BALB/c
mice according to the RNeasy minikit isolation procedure
(QIAGEN), and was individually analysed (5 animals/group) by
real-time reverse transcription PCR. Two mg samples of RNA
from different experimental groups of mice were first utilized for
cDNA synthesis by random hexamers (Invitrogen) using Super-
script II (Invitrogen). The synthesized cDNA was subjected to real-
time PCR with SYBR Green JumpStart Taq Ready Mix (Sigma)
and gene-specific primers in an iCycler PCR detector (Bio-rad)
according to the manufacturer’s instructions. The primers used for
amplification of IL-10, IL-4, IFNc, TNFa, TGFb and iNOS were
described previously [11]. The primer sequences for p19, p35, IL-
6, IL-17, TLR2, TLR4 and GAPDH are given in Table SI. The
relative quantization of products was determined by the
comparative DDCT method. Each gene of interest was normalized
to the ß-actin gene and the fold change was compared relative to
the normal control.
Isolation of iNKT cells from mouse spleen
iNKT cells from mouse spleen were isolated according to the
method of Benlagha et al. [62]. Mononuclear cells were obtained
from spleens of mice by purification over 35% Percoll gradient
centrifugation (Sigma-Aldrich). B-cells were depleted prior to
iNKT cell enrichment by using CD45R (B220) Microbeads
(Miltenyi Biotec). Subsequent isolation of iNKT cell was carried
out using a PE-conjugated CD1d tetramer loaded with a-GalCer
(Miltenyi Biotec) and anti PE-Microbeads at ice cold temperature
following the manufacturer’s instructions. The CD1d-tetramer
+
cells were labelled with PE-aGalCer-Cd1d-tetramer (Proimmune)
and PE-Cy5-conjugated anti-mouse TCRb (clone: H57-597,
hamster IgG2a; BD Biosciences) for further aGalCer-Cd1d-
tetramer
+ TCRb
+ enrichment by FACS, and are referred to as
NKT cells throughout the study. We gated further on the CD1d-
a-GalCer
2 PE-Cy5-anti-TCRb
+ PE-CD4
+ and are referred as the
iNKT depleted populations.
Cytokine analysis by ELISA
In a final volume of 0.2 mL, iNKT cells isolated from
experimental animals were adjusted to 1610
5 cells/mL and
mixed with 1:10 of autologous splenic adherent cells (1610
6
adherent cells) from individual mice (5 animals/group) of different
groups of experimental mice and were incubated for 24 h at 37uC
with or without 100 mg/mL GSPL. Adherent cells were obtained
by incubating 56l0
7 spleen cells in 90-mm glass petri dishes in
RPMl 1640 supplemented with penicillin/streptomycin, 10% fetal
calf serum, and 56M 2-mercaptoethanol for 3 hr at 37uC. Non-
adherent cells were removed, the adherent cells were washed (62)
with warm RPMI-1640 with gentle swirling and adherent cells
were gently detached using a rubber policeman. The release of
cytokines was measured in the supernatants by commercial ELISA
kits (Quantikine M; R&D Systems, Minneapolis, MN, USA; IL-
18, e-Bioscience). The detection limit of these assays was ,2.5,
,4.0, ,5.1, ,2.0, ,2.0, ,1.5, ,2.5, ,4.0, ,5.0, ,4.6, ,1.6,
and 10.0 pg/mL for IL-12p70, IL-12p40, TNF-a, IL-4, IL-13, IL-
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PMA (250 ng/mL; Sigma-Aldrich) and anti-mouse CD3 (1 mg/
mL; BD Biosciences) or medium only was used as positive and
negative controls, respectively. Appropriate isotype controls were
also analyzed. The data are represented as the mean 6 SD of all
the five individual animals per group under consideration.
Administration of neutralizing antibody
Blockade of IL-18, IL-23, IL-12, and IL-17 was carried with
100 mg of anti-mouse IL-18, IL-23, IL-12, and IL-17 Abs, clone
93-10 (R&D Systems), G23-8 and C17.8 (eBioscience) and TC11-
18H10 (Southern Biotech) respectively or an isotype matched
control on day 21, 0 and +1 of treatment with GSPL. For CD40L
blockade, anti-CD40L mAb MR1 (eBioscience) was added to the
cultures. IL-6 was blocked with 20 ng/200 mL anti IL-6 Ab, clone
MP5-20F3 (R & D Systems, rat IgG1) and IL-6R was blocked with
mouse IL-6R Ab (1 mg/mL, clone D7715A7, eBioscience, rat
IgG2b).
Immunofluorescent staining
For Ag-specific cytokine responses, splenocytes cultured with
either GSPL at 100 mg/mL concentration or no antigen (as a
negative control) were stained for intra-cytoplasmic cytokine, or
surfaced stained for TLR as described [16].
Transfection of siRNA to splenocytes
For siRNA transfection, cells were transfected with 1 mgo f
appropriate siRNA or control siRNA according to the manufac-
turer’s instructions (Santa Cruz Biotechnology).
Supporting Information
Figure S1 Thin layer chromatogram of GSPL and effect
of GSPL on BMDC viability and phagocytic activity. (A,B)
TLC of GSPL and b-glycosidase treated GSPL. Lane 1, GSPL;
lanes 2 and 3, a-galactosidase and b-galactosidase treated GSPL
respectively. The glycolipids in plate A were visualized with the
diphenyl amine reagent for glycolipids. Plate B was transferred to
PVDF membrane by TLC blotting and overlaid with biotinylated
Erythrina cristagalli lectin. A representative chromatogram devel-
oped with chloroform:methanol:0.25N ammonia in 0.25%
KCL(65:45:9) is shown. (C) BMDCs were incubated with various
concentrations of GSPL (50–400 mg/mL) for 24 h. Cell viability
was assessed by the MTT method. (D,E) Phagocytic activity of
GSPL treated BMDCs. FITC-coupled latex beads were co-
incubated with BMDCs in absence (D) and in presence of GSPL
(E). Extracellular beads were removed by extensive washing; the
cells were observed under fluorescence microscope. Scale bars,
10 mm.
(TIF)
Figure S2 Protective effect of GSPL on disease relapse.
LD-infected BALB/c mice were treated with GSPL (8 wk p.i.) and
were sacrificed every 3 months up-to 12 months and compared to
vehicle-treated infected controls. Bone marrow (A), splenic (B) and
hepatic (C) parasite burdens were determined as described in
Materials and Methods. Data represent the means 6 SD of 5 animals
per group and are representative of three individual experiments.
p,0.0001 at all time points after infection, compared with
respective infected control groups; paired two-tailed Student’s t-
test
(TIF)
Figure S3 GSPL mediated protection depends on TLR4.
(A) BMDCs were infected for 48 h with stationary phase 2
nd
passage LD promastigotes at a parasite/APC ratio of 20:1.
Infected BMDCs were treated with 100 mg/mL GSPL for 24 h.
Anti TLR2 and anti TLR4 antibodies and isotype controls were
added to parallel cultures and intracellular parasite number was
determined by Giemsa staining. (B–D) The viability and
phagocytic ability of the BMDCs treated with GSPL was assessed
as described in legend to Figure S1. (B) Viability of GSPL treated
BMDCs in presence of anti TLR2 and anti TLR4 antibodies. The
phagocytic activity of BMDCs in absence (C) and presence (D) of
GSPL. Experiments were done at least three times each and one
set of representative data is shown. Error bars represent mean 6
SD, n=3. * p,0.0001; paired two-tailed Student’s t-test.
(TIF)
Figure S4 FACS analysis of splenic adherent cells. Shown
is a representative APC sample. Region R1 defines all Cd11c
+
cells; region R2 defines all Cd11b
+ cells and region R3 defines all
Cd11b
+Cd11c
+ cells. Experiment was done at least three times.
(TIF)
Figure S5 Intracellular flow cytometric analysis of
cytokine profile in GSPL treated LD infected WT
BALB/c and C3H/HeJ mice. Sixty days LD infected animals
were treated with GSPL as described in the legend of Figure 1.
NKT cells from spleens of individual experimental BALB/c (A)
and C3H/HeJ (B) mice were identified as a-GC/CD1d
tetramer
+abTCR
+ cells (Ai,Bi) and after enrichment by magnetic
cell sorting (Aii,Bii;R1,R3) were further purified by FACS sorting
(Aiii,Biii;R2,R4). aGalCerCD1d-tetramer
+TCRb
+iNKT cells iso-
lated from experimental animals were mixed with autologous
splenic adherent cells as described for Figure 4. Cells were either
stimulated with GSPL (+GSPL) at 100 mg/mL or were treated
with medium only (2GSPL) for the time periods as mentioned in
the text. For the characterization of the cytokine profile, the T cells
were then stained using appropriate concentrations of monoclonal
antibody directed against the respective cytokines. To specifically
identify iNKT cells, we gated on cells that doubly stained with
fluorescent PE–CD1d–a-GalCer tetramers and PE-Cy5-anti-
TCRb (C;R5). The gated cells were further analyzed for the
expression of intracellular FITC-labeled cytokines. Numbers
above horizontal bars represent mean fluorescence intensity and
numbers below the bar represents percentage of cytokine positive
cells. Anti IL-12p70, anti IL-18 and anti IL-23p19 Abs or isotype
controls (data not shown) were added to parallel cultures and
intracellular IFN-c production was determined by FACS (Diii–v)).
D,L, IFN-c; E,M, TNF-a; F,N, IL-17A; G,O, IL-6; H,P, IL-13; I,
Q, IL-4; J,R, TGF-b and K, S, IL-10 expressions. Gray lines
depict un-stimulated controls and black lines indicate GSPL
stimulated cell. Data represent the mean 6 SD for five animals per
group. Data are representative of three experiments.
(TIF)
Figure S6 GSPL mediated induction of Th1/Th17
cytokines mRNA. Gene expression was done by comparative
CT method using real-time PCR. Fold change in m-RNA
expression profiles of A, IFN-c; B, IL-18; C, TNF-a; D, iNOS;
E, IL-17A; F, TGF-b; G, IL-6; H, IL-4; I, IL-13 and J, IL-10 in
splenic lymphocytes of LD-infected (infected control) and LD-
infected-GSPL treated (GSPL treated) mice. Results show mean 6
SD of five individual mice per group (*p,0.0001; **p,0.05 versus
corresponding infected control; paired two-tailed Student’s t-test).
Each gene was normalized to the housekeeping gene (b-actin)
before fold change was calculated to account for variations
between different samples.
(TIF)
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treatment of LD infected BALB/c mice reduced the anti-
leishmanial effect of GSPL. Sixty days LD infected BALB/c
mice were injected i.p. on days 21, 0, and +1 of GSPL treatment
either with isotype control antibody, anti-IL-12p70, anti IL-18, or
IL-23p19. Splenic parasite burden was determined as described in
Figure 1. Data represent the mean 6 SD of 3 animals per group,
and are representative of three individual experiments. *p,0.0001
compared with the LD infected control groups; paired two-tailed
Student’s t-test.
(TIF)
Figure S8 Kinetics of IL-17A production by iNKT cells of
cured mice. Sixty days LD infected animals were treated with
GSPL as described in the legend of Figure 1. Animals were
sacrificed 15 days after the last treatment. iNKT cells and NKT
depleted cell populations from spleens of individual experimental
BALB/c mice were isolated as described in legend to Figure 6.
Isolated T-cells were co-cultured with 1:10 of autologous splenic
adherent cells as described for Figure 4. Cells were stimulated with
GSPL at 100 mg/mL, 6 IL-6 Ab or 6 IL-6R Ab for the time
periods indicated and IL-17A in spleen cell culture supernatants
were determined by ELISA. Results show mean 6 SD of three
individual mice per group; *p,0.0001 versus corresponding Ab
treated group; paired two-tailed Student’s t-test. Results of one
from three independent experiments are shown.
(TIF)
Figure S9 GSPL induces IL-17, which is dependent on
IL-23. LD infected BALB/c mice were treated with GSPL or with
vehicle control only. After 15 days, adherent spleen cells co-
cultured with autologus iNKT cells were stimulated with GSPL as
described in Figure 6, with or without anti IL-23 Ab or isotype
controls. IL-17 was estimated in the supernatants by ELISA. IL-23
siRNA transfected adherent splenic cells were similarly cultured in
parallel. Data represent the mean 6 SD of 3 animals per group,
and are representative of three individual experiments.
*p,0.0001; paired two-tailed Student’s t-test.
(TIF)
Table S1 Real-time RT-PCR primer sequences.
(DOC)
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